Navigation Links
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Date:3/31/2008

in developed nations(7). The average duration between onset of symptoms and death due to complications of Alzheimer's disease is about 8-10 years(8). The burden to caregivers and health care costs can increase dramatically in the late stages of Alzheimer's disease, when patients cannot maintain independent function and are frequently bedridden.

To more completely characterize the disease-modifying effects of LY450139, a number of optional biomarker sub-studies will be available to patients. These optional sub-studies will utilize new brain-scanning techniques to determine the amount of amyloid beta plaque in the brain, employ other, more established scanning techniques to examine brain structure and function, and evaluate a number of additional biochemical measures of Alzheimer's disease. By determining the effect of LY450139 on these objective biomarkers, a more complete understanding of the effect of LY450139 on underlying Alzheimer's disease pathology is possible.

Additional information regarding the IDENTITY trial, including global recruitment sites, may be found by visiting http://www.clinicaltrials.gov or http://www.lillytrials.com, or by calling 1-877-CTLilly (1-877-285-4559).

About LY450139

LY450139 inhibits gamma secretase, an enzyme that cuts a protein, creating a shorter, sticky protein called amyloid beta. Alzheimer's disease theory suggests that some subtypes of amyloid beta clump together into plaques that eventually kill off brain cells. Clinical studies have examined the effect of LY450139 on amyloid beta in blood and cerebrospinal fluid. The most frequently occurring side effects experienced in earlier clinical studies with LY450139 include diarrhea, upset stomach, and fatigue. For a more complete listing of potential side effects, prospective clinical trial participants should refer to the informed consent do
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
2. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
3. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
4. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
5. Lilly Receives NCQA Design Certification for Depression Care Management Program
6. Lilly and Glenmark Pharmaceuticals Announce License Agreement
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
9. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
10. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
11. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen ... interim clinical data on intravenous belinostat,(PXD101), a ... treatment of cancer, are expected to be ... One oral and one poster presentation discussing ...
... WIRE)--Apr 18, 2007 - Critical,Therapeutics, Inc. (Nasdaq: ... a role in chronic inflammatory,autoimmune disease for ... mediator and nuclear DNA-binding protein, will be,published ... Immunology. The,publication demonstrates that HMGB1 is part ...
Cached Medicine Technology:CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5
(Date:7/10/2014)... could prove useful in treating small cell lung cancer - ... the Cancer Research UK Manchester Institute, based at The University ... teamed up with experts at AstraZeneca, as part of a ... as AZD3965 - on small cell lung cancer cells. , ... , also helps identify which patients are most likely to ...
(Date:7/9/2014)... If you think winning is one of the key determinants ... along with other mental bonuses ranked near the bottom of ... of 11 big fun factors, according to a new study. ... it comes to the "fun" factor, very little research had ... this elusive conceptuntil now. , The results of this study ...
(Date:7/9/2014)... reveal that sudden, acute episodes of low back pain ... humidity, air pressure, wind direction and precipitation. Findings published ... of the American College of Rheumatology (ACR), indicate that ... higher wind speed or wind gusts, but was not ... Organization (WHO) nearly everyone experiences low back pain at ...
(Date:7/9/2014)... Boston, MA -- Vasectomy was associated with a small ... for advanced or lethal prostate cancer according to a ... The researchers found that the association remained even among ... risk of lethal cancer cannot be explained by diagnostic ... to date to look at the link between vasectomy ...
(Date:7/9/2014)... told she had an aneurysm, she figured an invasive brain ... was devastated," said Wakulich, who is 56 years old and ... serious diagnosis. Then I met Dr. Bernard Bendok who told ... procedure. It was something I didn,t even know was an ... clinical trial to evaluate the safety and effectiveness of the ...
Breaking Medicine News(10 mins):Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2
... Chocolate Milk Can Help Athletes Refuel ... And Earn ... ... scored a,valuable spot on and off the court. Studies suggest the unique ... body after,exercise, making it an ideal post-exercise choice. Now high school teams,who ...
... more fruits and vegetables , , WEDNESDAY, March 12 (HealthDay ... healthy eating habits in children aged 2 to 5, ... at the University of Miami Miller School of Medicine, ... to eight subsidized child-care centers in Miami Dade County. ...
... Klein Renowned for IVF Success, NEWBURGH, N.Y., ... affiliate of The Mount Sinai Hospital, is proud ... with the addition of,Reproductive Endocrinologist Jeffrey Klein, M.D. ... director of the Westchester division of,Reproductive Medicine Associates ...
... , A researcher from the Physical Anthropological Laboratory ... the most complete database today to identify human remains ... computerised techniques for facial reconstruction. This method will reduce ... it will avoid the need to perform an expensive, ...
... donating stock to establish corporate foundation; Community ... helps care for the aging in Bay Area, ... is pleased to,announce its participation as the 200th ... to engaging high-growth,companies in corporate citizenship and philanthropic ...
... 12 Managed Health Care,Associates, Inc. (MHA) announces ... Member Study, the results of which will be,revealed ... 2008 in Las Vegas,Nevada., The report was ... 2007,and examined self-reported data for key operational elements ...
Cached Medicine News:Health News:Chocolate Milk + Exercise = A Winning Team 2Health News:Chocolate Milk + Exercise = A Winning Team 3Health News:Chocolate Milk + Exercise = A Winning Team 4Health News:Preschool Intervention Curbed Trend Toward Obesity 2Health News:Preschool Intervention Curbed Trend Toward Obesity 3Health News:SLCH Brings Infertility Specialist to Region 2Health News:Body identification by facial reconstruction will cost less time and money 2Health News:Caring.com Joins Entrepreneurs Foundation as 200th Member 2Health News:MHA to Release Findings of Independent Long Term Care Member Study 2
... The Thumper Board provides optimum head hyperextension, open ... intubation easier. Placed at strategic locations throughout ... CPR to be started immediately, and easy conversion ... patient application can be done in less than ...
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
Medicine Products: